Opdivo meets OS endpoint in esophageal cancer trial

Ono Pharmaceutical Co. Ltd. (Tokyo:4528) said anti-PD-1 mAb Opdivo nivolumab met

Read the full 110 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE